04 January 2024
04 January 2024
Agios plans to file regulatory approval for mitapivat by the end of the year after it met primary and secondary endpoints in the Phase III trial.
The most common reported adverse events did not differ from previous studies with most events reported as mild to moderate.
Longboard’s stock price has skyrocketed following the announcement of positive topline data.
A US court has granted the FTC's request to halt the acquisition due to concerns that it will promote anticompetitive practices.
The immuno-oncology company has also completed enrolment in a Phase I trial investigating its dendritic cell vaccine DOC1021.
The trial aims to fully explore the pharmacokinetics, pharmacodynamics, and safety of VENT-03.
The trial is designed to assess the efficacy of 100mg subcutaneously injected dose of verekitug given every 12 weeks.
The Part B open-label portion will assess a single ascending dose of inhaled RCT1100 in nine PCD patients.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
